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Abstract 
Background: Screening program tend to recognized patients in their early stage and consequently improve health 
outcomes. Cost-effectiveness of the abdominal aortic aneurysm (AAA) screening program has been scarcely studied 
in developing countries. We sought to evaluate the cost-effectiveness of a screening program for the abdominal 
aortic aneurysm (AAA) in men aged over 65 years in Iran.
Methods: A Markov cohort model with 11 mutually exclusive health statuses was used to evaluate the cost-effec-
tiveness of a population-based AAA screening program compared with a no-screening strategy. Transitions between 
the health statuses were simulated by using 3-month cycles. Data for disease transition probabilities and quality 
of life outcomes were obtained from published literature, and costs were calculated based on the price of medical 
services in Iran and the examination of the patients’ medical records. The outcomes were life-years gained, the quality-
adjusted life-year (QALY), costs, and the incremental cost-effectiveness ratio (ICER). The analysis was conducted for a 
lifetime horizon from the payer’s perspective. Costs and effects were discounted at an annual rate of 3%. Uncertainty 
surrounding the model inputs was tested with deterministic and probabilistic sensitivity analyses.
Results: The mean incremental cost of the AAA screening strategy compared with the no-screening strategy was 
$140 and the mean incremental QALY gain was 0.025 QALY, resulting in an ICER of $5566 ($14,656 PPP) per QALY 
gained. At a willingness-to-pay of 1 gross domestic product (GDP) per capita ($5628) per QALY gained, the probability 
of the cost-effectiveness of AAA screening was about 50%. However, at a willingness-to-pay of twice the GDP per 
capita per QALY gained, there was about a 95% probability for the AAA screening program to be cost-effective in Iran.
Conclusions: The results of this study showed that at a willingness-to-pay of 1 GDP per capita per QALY gained, a 
1-time AAA screening program for men aged over 65 years could not be cost-effective. Nevertheless, at a willingness-
to-pay of twice the GDP per capita per QALY gained, the AAA screening program could be cost-effective in Iran. Fur-
ther, AAA screening in high-risk groups could be cost-effective at a willingness-to-pay of 1 GDP per capita per QALY 
gained.
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Background
An aneurysm is characterized as a pathological, perma-
nent dilation of a vessel [1]. The main agreed-upon defi-
nition of the problem is based on the diameter size of the 
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vessel. For an abdominal aortic aneurysm (AAA), a diam-
eter size of greater than 3 cm, with an increased risk for 
rupture, is accepted as an aneurysm [2].
Investigations in the United States, United Kingdom, 
Sweden, and Australia have indicated that AAA may 
affect 1.6% to 7.2% of the population older than 50 years. 
Also, in terms of prevalence, AAA is 4 to 15 times more 
common in men than in women and its incidence rises in 
tandem with age [3–6].
Approximately 200,000 cases with AAA are diagnosed 
annually in the United States, with nearly 15,000 cases 
of this total at high risk of rupture. The aortic rupture 
is often fatal, and between 59 and 83% of these patients 
expire before admission to the hospital. After acute rup-
ture, the mortality rate of emergent surgery is more than 
40%. Indeed, only between 10 and 25% of cases with aor-
tic rupture are likely to survive until discharge time [7–9].
The risk of rupture is related to the size of the aneu-
rysm. In other words, an increase in the size of the dila-
tion is concomitant with an increase in the chance of 
rupture. The risk of aortic rupture in women is 4 times 
that in men and twice as high in smokers as in nonsmok-
ers [10, 11].
There is currently a dearth of data on the global eco-
nomic burden and total cost of AAA; however, the aver-
age hospitalization time and the cumulative cost of 
unruptured and ruptured aneurysms are, respectively, 6.7 
and 10.7 days and $59,000 and $93,000 [12].
Open surgical repair (OSR) and endovascular aneu-
rysm repair (EVAR) are 2 accepted treatment modalities 
for AAA. Research shows that the short-term morbidity 
rate in EVAR is lower than that in OSR; still, it appears 
that EVAR increases the risk of reoperation and long-
term mortality [13–16]. Such findings denote the use-
fulness of screening methods for the early diagnosis of 
AAA, especially in light of the fact that not only are most 
patients with AAA asymptomatic and complications 
increase the mortality rate but also therapeutic inter-
ventions are expensive. The most common screening 
strategies for the early detection of AAA are ultrasound 
sonography and computed tomography angiography 
(CTA). Aortic sizing is reportedly more accurate on CTA, 
at the expense of radiation exposure and the risk of con-
trast-induced kidney injury. Ultrasound sonography is 
now deemed the gold standard for AAA screening on the 
strength of its accessibility, generalizability, and safety 
[17–19].
In the early years of the current century, several rand-
omized clinical trials showed that ultrasound screening 
for AAA had a significant effect on reducing its mortality 
[20–22]. Similarly, several economic evaluation studies 
in Western countries have reported that AAA screening 
in men over 65 years old is highly cost-effective [23–27]. 
Such results have prompted some medical societies such 
as the European Society for Vascular Surgery and the 
United States Preventive Services Taskforce to recom-
mend AAA screening [28, 29], paving the way for the 
implementation of nationwide AAA screening programs 
in several Western countries [30].
The Healthcare system in Iran comprises three sectors 
including public, private and not-for-profit. Although all 
sectors are involved in providing secondary and tertiary 
healthcare services, Primary healthcare services such as 
maternal and child care, screening programs, etc., are 
mainly funded and provided by the public sector [31]. 
National Health Network was one of the major health 
reforms in Iran intended to decrease the inequities and 
expand the health care coverage in deprived areas. The 
addition of family physician program also increases the 
potentiality for a more homogenous coverage of health 
facilities [32]. Screening as a preventive community-
based intervention play a pivotal role in a primary health 
care system. Several national screening program mainly 
on cancer prevention have been launched, however, most 
of them are not based on national studies and lack cost–
benefit analysis [31]. The problem is more aggravated in 
cardiovascular diseases like aortic aneurysm. Research 
in Asia is hampered by the current paucity of informa-
tion about the prevalence of AAA. Be that as it may, the 
available data indicate that the prevalence of the dis-
ease in Asian countries is lower than that in European 
and American countries [33–35]. Accordingly, given the 
uncertainty as to the cost-effectiveness of AAA screening 
in Asian countries, we aimed to evaluate the cost-effec-
tiveness of a 1-time screening program for AAA in men 
aged over 65 years in Iran.
Methods
Model structure
In the present study, a previously published Markov 
model [36, 37] was employed to evaluate the long-term 
costs and clinical outcomes of the screening strategy in 
comparison with the no-screening strategy (Fig.  1). The 
Markov model considers 11 mutually exclusive health 
statuses to simulate AAA progression. The health sta-
tuses in the model are as follows: no AAA, 6 AAA sta-
tuses (3 undetected AAAs and 3 detected AAAs), 2 
postoperative statuses (post-EVAR and post-OSR), 
death from AAA, and death from other causes. Each of 
the 3 AAA statuses represents different sizes of aneu-
rysms: small (3–4.4 cm), medium (4.4–5.4 cm), and large 
(> 5.5 cm). Each arrow in Fig. 1 characterizes a possible 
transition. Undetected AAAs may be detected by screen-
ing or opportunistically. If an aneurysm is detected, ultra-
sound monitoring is conducted annually for small AAAs 
and every 6  months for medium AAAs. Patients with 
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aneurysms greater than 5.5  cm undergo elective repair 
surgery. Rupture may occur in all detected and unde-
tected AAAs. Rupture is followed by 2 scenarios: either 
patients may die and transit to the status of death from 
AAA or they may undergo an emergency repair surgery. 
OSR and EVAR are the suggested surgical interventions 
for both elective and emergency repair operations. The 
main complications of surgical methods are myocardial 
infarction, stroke, renal failure, and death. After surgery, 
patients may transit to one of the 2 postoperative statuses 
depending on the type of surgery or die and transit to the 
status of death from AAA. In all living statuses, patients 
may die due to other causes and transit to the status of 
death from other causes.
Model parameters
The parameters of the Markov model utilized in the 
current investigation are depicted in Table  1. The 
prevalence of AAA was extracted from a previous 
study in Iran and studies in other countries [38–40]. 
On the assumption that the size distribution of aneu-
rysms in Iran was similar to that in the United King-
dom, the value at the initial cycle was obtained from 
an AAA screening program run by that country’s 
Fig. 1 Markov model for both the screening strategy and the no-screening strategy. AAA abdominal aortic aneurysm, EVAR endovascular aneurysm 
repair, OSR open surgical repair
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National Health System [36]. The probabilities of tran-
sition between the AAA statuses and the probabilities 
of rupture in the different AAA statuses were extracted 
from a systematic review study [41] and an economic 
evaluation study conducted in the United Kingdom 
[36]. The proportion of each surgical type in Iran was 
obtained by an expert panel. Further, the probabil-
ity of death after emergency and elective surgery was 
Table 1 Parameters used in the Markov model to evaluate screening for AAA 
NA not applicable, AAA abdominal aortic aneurysm, EVAR endovascular aneurysm repair, OSR open surgical repair
a Mortality rates related to AAA repair were defined as those that occurred within 30 days after surgery
Variable Point estimate (range) Distribution Source
Prevalence of AAA 0.03 (0.01–0.04) Beta [36–38]
Proportion of small AAAs 0.789 Dirichlet [34]
Proportion of medium AAAs 0.12 Dirichlet [34]
Proportion of large AAAs 0.091 Dirichlet [34]
Transition probabilities (3-monthly)
 From no AAA to small AAA 0.00207 (0.0013–0.0029) Gamma [34]
 From small AAA to medium AAA 0.037 (0.033–0.042) Beta [39]
 From medium AAA to large AAA 0.175 (0.119–0.231) Beta [39]
Probability of rupture (3-monthly)
 In small AAA 0.00023 (0.00013–0.00038) Beta [39]
 In medium AAA 0.00160 (0.00043–0.00588) Beta [39]
 In undetected large AAA 0.0282 (0.01974–0.03666) Beta [34]
 In detected large AAA 0.0125 (0.008–0.018) Beta [34]
 In detected large AAA contraindicated for surgery 0.0282 (0.01974–0.03666) Beta [34]
 Probability of opportunistic detection 0.0114 (0.00798–0.01482) Beta [34]
 Probability of emergency surgery after rupture 0.368 (0.200–0.500) Beta [34]
 Probability of elective surgery if large AAA 0.918 (0.85–0.95) Beta [35]
 Probability of reoperation after EVAR (year 1–2) 0.063 (0.0441–0.0819) Beta [35]
 Probability of reoperation after OSR (year 1) 0.039 (0.0273–0.0507) Beta [35]
 Proportion of patients undergoing screening (%) 0.75 (0.65–0.85) Beta Expert opinion
 Proportion of EVAR as emergency surgery (%) 0.05 (0–0.1) Beta Expert opinion
 Proportion of EVAR as elective surgery (%) 0.8 (0.7–0.9) Beta Expert opinion
Death  aftera
 Elective EVAR 0.013 (0.004–0.023) Beta [35, 40, 42]
 Elective OSR 0.030 (0.021–0.050) Beta [34, 42]
 Emergency EVAR 0.307 (0.152–0.492) Beta [35, 42]
 Emergency OSR 0.5 (0.35–0.65) Beta [41]
Health-related quality of life (EQ-5D index)
 65–69 years old 0.83 NA [35]
 70–74 years old 0.81 NA [35]
 75–79 years old 0.79 NA [35]
 80+ years old 0.74 NA [35]
Health-related disutilities (EQ-5D index)
 Post EVAR and OSR − 0.02 NA [43]
 All-cause mortality Age-specific NA [44]
 Discount rate (%) 3 (0–6) NA Expert opinion
Cost of
 EVAR (per patient) (US$) 12,433 (8289–20,722) Gamma Our estimation
 OSR (per patient) (US$) 6442 (4295–10,737) Gamma Our estimation
 Screening test (ultrasound) per patient (US$) 39.17 (25.25–57.29) Normal Our estimation
 Small AAA follow-up (per cycle) (US$) 9.79 (6.31–14.32) Normal Our estimation
 Medium AAA follow-up (per cycle) (US$) 19.58 (12.63–28.64) Normal Our estimation
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extracted from previous studies conducted in Iran and 
other countries [36, 37, 42–44]. The probabilities of 
reoperation after EVAR and OSR and health-related 
quality of life for men of different ages were extracted 
from a study by Zarrouk et  al. [37]. Disutility due to 
surgery was obtained from an investigation by Lederle 
et al. [45]. Age-specific all-cause mortality rates for the 
Iranian population were obtained from the available 
Iranian life tables [46].
The cost for the screening and follow-up of a patient 
with a detected small or large AAA was calculated 
based on the price of physician visits and ultrasound 
examinations in Iran in 2017. The costs of EVAR and 
OSR were estimated by examining the medical records 
of 110 hospitalized patients in 2 referral hospitals in 
Iran (Rajaie Cardiovascular Medical and Research 
Center and Sina Hospital). Only direct medical costs 
were calculated; these costs encompassed those of all 
diagnostic and treatment modalities—namely hospi-
talization, laboratory, imaging, physician visit, surgery, 
complications, and treatment. All costs were converted 
to US dollars according to the official exchange rate, 
which was $1 = 34,212 IR Rials [the purchasing power 
parity (PPP) exchange rate $1 = 12,993 IR Rials] in 2017 
[47].
Analysis
Two identical cohorts of men aged 65  years old were 
simulated. The first cohort was invited to be screened 
with ultrasound sonography, but the second cohort was 
not invited. The model applied a 3-month cycle length 
for a lifetime horizon. All future costs and effects were 
discounted at a 3% annual rate. A half-cycle correction 
was used for both costs and effects on the assump-
tion that both costs and effects occur halfway through 
a model cycle. The outcomes were life-years gained, 
the quality-adjusted life-year (QALY), and costs. The 
analysis was carried out for a lifetime horizon from the 
point of view of the payer. Additionally, the incremental 
cost-effectiveness ratio (ICER) was calculated to com-
pare the 2 strategies of screening and no screening. The 
TreeAge Pro software (TreeAge Pro Software, Inc, Wil-
liamston, MA) was utilized for data modeling.
Sensitivity analysis
Deterministic and probabilistic sensitivity analyses were 
undertaken to allow for parameter uncertainty. The range 
used for the uncertainty around the point estimate of 
each variable and the distribution used in the probabilis-
tic sensitivity analysis are presented in Table 1.
Results
Base‑case analysis
The main results from the base-case analysis are shown in 
Table 2. The mean incremental cost of the AAA screen-
ing strategy compared with the no-screening strategy was 
$140 ($369 PPP) and the mean incremental QALY gain 
was 0.025 QALY, resulting in an ICER of $5566 ($14,656 
PPP) per QALY gained. The incremental health gain in 
terms of life-year was 0.034, yielding an ICER of $4106 
($10,812 PPP) per life-year gained.
Sensitivity analysis
Most of the parameters in the 1-way sensitivity analy-
sis had a limited effect on the results. The variables that 
influenced the model outcomes the most were the dis-
count rate, the cost of EVAR, the probability of rupture in 
undetected large AAAs, the cost of screening tests, and 
the prevalence of AAA (Fig. 2). The results of the 1-way 
sensitivity analysis for the selected variables are pre-
sented in Table 3. At a 6% discount rate on health gains 
and costs, the ICER changed to about $7334 per QALY 
gained. (The undiscounted equivalent was about $4151 
per QALY gained). When the cost of EVAR was increased 
to $20,722, the ICER rose to $8409 per QALY gained, 
while decreasing the cost of EVAR to $8289 diminished 
the ICER to $4144 per QALY gained. A change in the 
probability of the rupture of undetected large AAAs 
between the lower and upper limits led to a variation 
of the ICER of between $7524 and $4618 per QALY 
gained. Moreover, an increase or a decrease in the cost 
of screening tests by about 40% resulted in a variation of 
the ICER of between $5153 and $6103 per QALY gained. 
Finally, when the prevalence of AAA was reduced to 1%, 
Table 2 Incremental cost-effectiveness ratio of an abdominal aortic aneurysm screening strategy compared with no screening
QALY quality-adjusted life-year, LYG life-years gained, ICER incremental cost-effectiveness ratio
Strategy Average Incremental ICER





No screening 267 8.780 10.890 – – – – –
Screening 407 8.806 10.924 140 0.025 0.034 5566 4106
Page 6 of 10Daroudi et al. Cost Eff Resour Alloc           (2021) 19:29 
the ICER rose to $7890 per QALY gained; and when the 
prevalence was increased to 4%, the ICER dropped to 
$5275 per QALY gained.
Probabilistic sensitivity analysis
The cost-effectiveness acceptability curve at different 
thresholds of willingness to pay (Fig.  3) shows that the 
probability of the cost-effectiveness of AAA screening 
was 0.5 at a threshold of $6000 per QALY gained and 
0.95 at a threshold of $12,000 per QALY gained.
Discussion
In this study, we investigated the cost-effectiveness of 
a 1-time AAA screening program for men aged over 
65  years in Iran. Our analysis showed that at a willing-
ness-to-pay of 1 gross domestic product (GDP) per 
capita ($5628 based on real market exchange rate and 
$14,819 based on PPP exchange rate) per QALY gained, 
the probability of the cost-effectiveness of AAA screen-
ing was about 50%; while at a willingness-to-pay of twice 
the GDP per capita per QALY gained, there was approxi-
mately a 95% probability for the AAA screening program 
to be cost-effective in Iran. To the best of our knowledge, 
the present study is the only investigation to analyze the 
cost-effectiveness of an AAA screening program in a 
developing country.
Our sensitivity analysis revealed that our results were 
sensitive to the prevalence of AAA. Based on our 1-way 
sensitivity analysis results, AAA screening could be cost-
effective at a threshold of 1 GDP per capita ($5628) per 
QALY gained, if the prevalence of AAA in Iran was 4% 
or greater. Furthermore, AAA screening could be cost-
effective at a threshold of twice the GDP per capita per 
QALY gained, if the prevalence of AAA in Iran was 1% or 
greater.
Recent years have witnessed a change in the epi-
demiology of AAA in Western countries, the most 
striking of which is the significantly reduced preva-
lence rate of AAA owing to alterations in smoking 
habits, followed by the improved management of car-
diovascular risk factors [35, 48]. Although these epi-
demiological changes have raised questions over the 
cost-effectiveness of AAA screening, the results of 
recent economic evaluation studies in Western coun-
tries have demonstrated that AAA screening in men 
aged 65 years or above is still cost-effective in the new 
context [36, 37, 44, 49, 50]. There is, however, no evi-
dence of a decrease in the prevalence of AAA in Asian 
countries, including Iran [33, 40]. Our extensive lit-
erature search showed only a few studies on the prev-
alence of AAA in Iran [39, 51, 52]. The salient point 
as regards these investigations is that their focus on 
special patient groups greatly lessens the applicability 
of their results to the general population of Iran. Mir-
sharifi et al. [39] reported a prevalence rate of 10% for 
AAA in men older than 65 years from among patients 
who referred for ultrasound sonography to 3 differ-
ent centers in Tehran, Iran, in the year 2008. Shirani 
et al. [52] found a prevalence rate of 3.8% for AAA in 
men aged over 65 years from among the candidates for 
coronary artery bypass graft surgery in Tehran Heart 
Center. Recent reports on the prevalence of AAA in 
Europe in the last decade have shown a clear decline 
significantly related to successful strategies for risk 
factor modification [37, 53]. In contrast, the current 
status of the strategies aimed at modifying AAA risk 
Fig. 2 Tornado diagram for 1-way sensitivity analyses
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Table 3 Result of the 1-way sensitivity analysis of the selected variables
AAA abdominal aortic aneurysm, EVAR endovascular aneurysm repair, OSR open surgical repair
Variable Cost (s) QALY ICER 
($ per 
QALY)No screening Screening Increment No screening Screening Increment
Discount rate (%)
 0 364 512 148 11.005 11.040 0.036 4151
 0.6 199 332 133 7.182 7.200 0.018 7334
Cost of EVAR ($)
 8289 203 308 104 8.780 8.806 0.025 4144
 20,722 393 604 212 8.780 8.806 0.025 8409
Probability of the rupture in undetected large AAAs (3-monthly)
 0.0197 267 406 139 8.799 8.817 0.018 7524
 0.0367 266 406 141 8.765 8.796 0.031 4618
Cost of the screening test (ultrasound) per patient ($)
 25 267 396 130 8.780 8.806 0.025 5153
 57 267 420 154 8.780 8.806 0.025 6103
Prevalence of AAA (%)
 0.01 235 338 103 8.795 8.812 0.017 7890
 0.04 298 475 177 8.766 8.799 0.034 5275
Probability of death after emergency OSR
 0.35 267 407 140 8.786 8.809 0.023 5984
 0.65 266 406 140 8.775 8.802 0.027 5203
Probability of emergency surgery after rupture
 0.2 241 387 147 8.771 8.800 0.028 5233
 0.5 287 422 135 8.787 8.810 0.023 5886
Proportion of EVAR as elective surgery (%)
 0.7 255 388 133 8.780 8.805 0.025 5311
 0.9 278 425 147 8.781 8.806 0.025 5818
Transition probabilities from medium AAA to large AAA (3-monthly)
 0.119 257 391 135 8.788 8.811 0.023 5833
 0.231 271 414 143 8.776 8.802 0.026 5419
Probability of death after elective EVAR
 0.004 267 407 140 8.781 8.807 0.026 5443
 0.023 266 406 140 8.780 8.804 0.025 5709
Fig. 3 Cost-effectiveness acceptability curve for abdominal aortic aneurysm screening. QALY quality-adjusted life-year
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factors in developing countries would logically hint at 
a higher rate of AAA incidence. Assuming a compa-
rable status concerning the prevalence of AAA in the 
general populations of men aged 65 years or above in 
Europe and Iran, we can conclude that AAA screen-
ing could not be cost-effective. Still, the fact that local 
studies indicate relatively high rates of AAA in high-
risk groups would bolster the argument in favor of 
screening such patients.
More recently, the results of a systematic review 
study commissioned by the United States Preventive 
Services Task Force showed that 1-time AAA screen-
ing in men 65  years or older was associated with 
decreased AAA-related mortality and rupture rates 
and increased rates of elective surgery, but it was not 
associated with all-cause mortality benefits and long-
term differences in the quality of life resulting from 
screening [54]. Based on these findings, the said task 
force recommended 1-time screening for AAA with 
ultrasonography in men aged 65 to 75 years who have 
ever smoked and selective screening for AAA with 
ultrasonography in men aged 65 to 75 years who have 
never smoked rather than routinely screening all men 
in this group [55].
The cost of EVAR was another variable that greatly 
influenced the results of our model. Based on expert 
opinion in this study, EVAR was more popular as the 
first therapeutic strategy in patients undergoing AAA 
treatment in Iran; consequently, we assumed that 80% 
of elective surgical operations were performed via 
EVAR. Although by comparison with OSR, the EVAR 
procedure has a favorable hospital course, its superior-
ity has never been proven and its long-term efficacy has 
been challenged recently [56, 57]. The result of a sys-
tematic review and meta-analysis conducted by Bulder 
et  al. [56] showed that the 30-day mortality rate for 
EVAR was lower than that with OSR (1.16 vs. 3.27%), 
but the long-term survival rates were similar for EVAR 
and OSR (hazard ratio: 1.01, 1.00, and 0.98 for 3, 5, and 
10  years, respectively). In another systematic review 
study, Chen et  al. [57] found that OSR and EVAR had 
similar all-cause mortality over a 5-year follow-up, 
which was maintained after at least 10 years of follow-
up. The authors also reported that a significantly lower 
proportion of their patients undergoing open repair 
required re-intervention (odds ratio: 0.38, 95% con-
fidence interval: 0.24 to 0.64), which was maintained 
over 5 years of follow-up. Based on our estimations, the 
mean cost of EVAR was about twice the mean cost of 
OSR in Iran. Therefore, since OSR is comparable with 
EVAR at least in terms of long-term efficacy, it is pos-
sible to boost the likelihood of the cost-effectiveness of 
AAA screening by using OSR in lieu of EVAR.
Limitation
In this study, to investigate the cost-effectiveness of 
AAA screening in Iran, we used a Markov model, the 
validity of which was confirmed in previous studies [26, 
36, 37]. Given the scarcity of data regarding some vari-
ables such as the progress and rupture rates of AAA in 
Iran, in this study, we assumed that the values of these 
variables in Iran are the same as in western countries. 
However, these variables may be context-specific and 
their values in Iran may be different from Western 
countries. Further research on the natural history of 
the AAA in Iran is needed to fill this data gap.
Conclusion
In conclusion, our results showed that at a willing-
ness-to-pay of 1 GDP per capita ($5628) per QALY 
gained, a 1-time AAA screening program for men aged 
65  years or above could not be cost-effective; whereas 
at a willingness-to-pay of twice the GDP per capita per 
QALY gained, the AAA screening program could be 
cost-effective in Iran. In addition, AAA screening in 
high-risk groups could be cost-effective at a willing-
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